Ticker Symbol: TOS/TSX
Shares Outstanding: 47,863,402
QUEBEC CITY, Dec. 11 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS)
announces the sale of its 24th 125L Ozone Sterilizer to date, this time to a
Canadian hospital located in the Eastern part of the Country.
"We are very happy to see a second sale come early in the month, as we
are dedicating every effort toward closing more business before year end",
said Jocelyn Vézina, CEO for TSO3 Inc.
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology whit high commercial potential. The Company's first product, the
125L Ozone Sterilizer, is designed for sterile processing centers in the
In contrast to other methods used, the ozone sterilization process
developed and patented by TSO3 meets all standards required by the evolution
in sterilization needs, which are: significant costs savings, increased safety
for patients and hospital staff, and a "green" environmentally safe process.
The Company believes that its technology represents an advantageous
replacement solution to other low temperature sterilization processes
currently used in hospitals.
The 125L Ozone Sterilizer is cleared for commercialization by the US Food
and Drug Administration and by Health Canada. TSO3 is in commercialization
phase for this first product since 2006.
TSO3 currently has more than 72 employees, about half of whom work in the
sales and marketing team.
For more information about TSO3, visit the Company's Web site at
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of
any financing undertaken by TSO3) are forward-looking statements that
involve certain risks, uncertainties and hypotheses, including, but not
limited to, general business and economic conditions, the condition of
the financial markets, the ability of TSO3 to obtain financing on
favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Caroline Côté, Director, Corporate
Communications & IR, (418) 651-0003, Ext. 237, firstname.lastname@example.org; Source: TSO3